Ergotamine + Caffeine


Thông tin thuốc gốc
Chỉ định và Liều dùng
Oral
Migraine
Adult: Ergotamine 1 mg and caffeine 100 mg tab
Initially, 2 tabs as a single dose at the 1st sign of an attack. If symptoms persist or recur, may give 1 tab every 30 minutes as necessary. Max: 6 tabs/attack or 6 tabs daily. Max weekly dose: 10 tabs. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).

Rectal
Migraine
Adult: Ergotamine 2 mg and caffeine 100 mg supp
Initially, 1 supp at the 1st sign of an attack. If symptoms persist or recur, may give 1 supp after 1 hour as necessary. Max: 2 supp/attack. Max weekly dose: 5 supp. Dosing recommendations may vary among individual products and between countries (refer to specific product guidelines).
Suy thận
Contraindicated.
Suy gan
Contraindicated.
Cách dùng
May be taken with or without food.
Chống chỉ định
Peripheral vascular disease, CHD, hypertension, sepsis, shock, temporal arteritis, hemiplegic or basilar migraine. Renal and hepatic impairment. Pregnancy (including women of childbearing potential) and lactation. Concomitant use with potent CYP3A4 inhibitors and other vasoconstrictor agents.
Thận trọng
Not indicated for prolonged daily use. Elderly.
Tác dụng không mong muốn
Significant: Cardiovascular effects (e.g. vasospasm, vasoconstriction, myocardial toxicity). Prolonged use: Ergotism (resulting in peripheral vascular ischaemia and gangrene), pleural and/or retroperitoneal fibrosis (rare), fibrotic valve thickening (e.g. aortic, mitral, tricuspid), headache; solitary rectal or anal ulcers (rectal).
Gastrointestinal disorders: Nausea, vomiting (not migraine-related), abdominal pain, diarrhoea.
Musculoskeletal and connective tissue disorders: Pain or weakness in extremity.
Nervous system disorders: Dizziness, paraesthesia, hypoaesthesia.
Vascular disorders: Cyanosis.
Thông tin tư vấn bệnh nhân
This drug may cause dizziness, if affected, do not drive or operate machinery.
Chỉ số theo dõi
Obtain BUN, serum creatinine, LFTs (at baseline). Asses CV status prior to initiating treatment and periodically thereafter. Monitor for signs of peripheral ischaemia.
Quá liều
Symptoms: Nausea, vomiting, abdominal pain, lightheadedness, headache, drowsiness, confusion, tachycardia or bradycardia associated with hypotension, dizziness, respiratory depression, gangrene, shock, coma, convulsions; numbness, tingling, pain and cyanosis of the extremities associated with diminished or absent peripheral pulses. Rarely, MI. Management: Symptomatic treatment. Administer activated charcoal for orally ingested drug. May perform gastric lavage for recent oral ingestion. May administer IV peripheral vasodilators (e.g. nitroprusside, phentolamine or dihydralazine), apply warmth and nursing care to the affected area for severe vasospastic reactions. May give nitroglycerin for coronary constriction.
Tương tác
Ergotamine: Enhanced vasoconstriction effect with other vasoconstrictor agents such as drugs containing ergot alkaloids, sumatriptan, other 5-HT1 receptor agonists and nicotine. Increased risk for vasospastic reaction with less potent CYP3A4 inhibitors (e.g. saquinavir, nefazodone, fluconazole, fluoxetine, fluvoxamine, zileuton, metronidazole, clotrimazole), β-blockers (e.g. propranolol). May cause serotonin syndrome with serotonin reuptake inhibitors (e.g. amitriptyline). Decreased pharmacological activity with CYP3A4 inducers (e.g. rifampicin, nevirapine).
Caffeine: Concurrent use with fluoroquinolones, mexiletine and oral contraceptives may increase plasma exposure to caffeine. May cause a rise in blood pressure with sympathomimetics. May lead to excitation and hallucinations with enoxacin.
Potentially Fatal: Ergotamine: Increased risk for vasospasm leading to cerebral and/or peripheral ischaemia with potent CYP3A4 inhibitors such as azole antifungals (e.g. ketoconazole, itraconazole, voriconazole), HIV protease or reverse transcriptase inhibitors (e.g. ritonavir, nelfinavir, indinavir, delavirdine), macrolide antibiotics (e.g. erythromycin, clarithromycin, troleandomycin).
Tương tác với thức ăn
Ergotamine: Increased risk for vasospasm with grapefruit juice.
Tác dụng
Description:
Mechanism of Action: Ergotamine is an ergot alkaloid derivative which has vasoconstrictor effects by stimulating the α-adrenergic and serotonin (5-HT) receptors. Its useful effect in migraine is mainly due to its agonist properties at 5-HT1B and 5-HT1D receptors. Additionally, it has a specific vasotonic action on the distended extracranial arteries which results in the abortion of migraine attacks.
Caffeine is a methylxanthine which inhibits the phosphodiesterase enzyme, therefore increasing the levels of 3',5'-cyclic adenosine monophosphate (cAMP). It increases and accelerates the enteral absorption of ergotamine thus, enhancing the vasoconstrictive effect without the need of increasing the dosage of ergotamine.
Pharmacokinetics:
Absorption: Ergotamine: Bioavailability: Approx ≤5% (oral and rectal). Time to peak plasma concentration: 2 hours (oral).
Caffeine: Rapidly and almost completely absorbed from the gastrointestinal tract.
Distribution: Ergotamine: Crosses the placenta and enters breast milk. Volume of distribution: 1.85 L/kg. Plasma protein binding: Approx 93-98%.
Caffeine: Widely distributed throughout the body. Crosses the placenta; enters breast milk (small amounts). Volume of distribution: 0.6 L/kg. Plasma protein binding: 36%.
Metabolism: Ergotamine: Extensively metabolised in the liver by CYP3A4 isoenzyme. Undergoes high first-pass metabolism.
Caffeine: Almost completely metabolised in the liver via oxidation, demethylation and acetylation by CYP1A2 isoenzyme.
Excretion: Ergotamine: Via faeces (90%, mainly as metabolites); urine (approx 4%). Elimination half-life: 2-2.5 hours.
Caffeine: Via urine (1%, as unchanged drug). Elimination half-life: Approx 3-7 hours.
Đặc tính

Chemical Structure Image
Ergotamine

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 8223, Ergotamine. https://pubchem.ncbi.nlm.nih.gov/compound/Ergotamine. Accessed Mar. 29, 2023.


Chemical Structure Image
Caffeine

Source: National Center for Biotechnology Information. PubChem Compound Summary for CID 2519, Caffeine. https://pubchem.ncbi.nlm.nih.gov/compound/Caffeine. Accessed Mar. 29, 2023.

Bảo quản
Tab: Store between 20-25°C. Protect from light. Rectal supp: Store between 2-8°C.
Phân loại MIMS
Thuốc trị đau nửa đầu
Phân loại ATC
N02CA52 - ergotamine, combinations excl. psycholeptics ; Belongs to the class of ergot alkaloids preparations. Used to relieve migraine.
Tài liệu tham khảo
Anon. Caffeine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 30/01/2023.

Anon. Ergotamine and Caffeine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 30/01/2023.

Anon. Ergotamine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 30/01/2023.

Buckingham R (ed). Caffeine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 30/01/2023.

Buckingham R (ed). Ergotamine Tartrate. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 30/01/2023.

Cafergot, Cafergot-PB (Advanz Pharma [HK]). MIMS Hong Kong. http://www.mims.com/hongkong. Accessed 24/03/2023.

Caffox (Imeks Pharma Sdn. Bhd.). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 23/03/2023.

Ergotamine Tartrate and Caffeine Tablet, Film Coated (Cintex Services, LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 23/03/2023.

Migergot Suppository (Cosette Pharmaceuticals, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed. Accessed 30/01/2023.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Ergotamine + Caffeine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in